IL0006290147
© Globe Newswire
12.12.2025
TEVA
LISTED
TLV
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
News Preview
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day,...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
TEVA
LISTED
TLV
Teva Releases Q4 2025 Aide Memoire
News Preview
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the “Investors” page on its website....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
TEVA
LISTED
TLV
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
News Preview
PARSIPPANY, N.J. and TEL AVIV, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for olanzapine extended-release injectable suspension (TEV-'749)...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
26.11.2025
TEVA
LISTED
TLV
Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva®
News Preview
TEL AVIV, Israël, 26 nov. 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, filiale de Teva Pharmaceutical Industries Ltd. (NYSE : et TASE : TEVA), annonce que la Commission européenne (CE) vient d’accorder des autorisations de mise en marché visant ses deux candidats biosimilaires au dénosumab, à savoir PONLIMSI, un biosimil...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
25.11.2025
TEVA
LISTED
TLV
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
News Preview
TEL AVIV, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced that the European Commission (EC) has granted marketing authorizations for its two denosumab biosimilar candidates – PONLIMSI, a biosimilar to Prolia®1 and DEGEVMA, a bio...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.11.2025
TEVA
LISTED
TLV
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
News Preview
TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of executive management will present at three upcoming investor conferences in December as follows:...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2025
TEVA
LISTED
TLV
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
News Preview
PARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new data from the ongoing, real-world IMPACT-TD Registry. The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
TEVA
LISTED
TLV
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
News Preview
For an accessible version of this Press Release, please visit www.tevapharm.com...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
TEVA
LISTED
TLV
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November
News Preview
TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in November as follows:...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2025
TEVA
LISTED
TLV
Teva et Prestige Biopharma concluent un accord de licence pour la commercialisation de Tuznue® en Europe
News Preview
TEL AVIV, Israël, 21 oct. 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, une filiale de Teva Pharmaceutical Industries Ltd. (NYSE et TASE : TEVA), a conclu un accord de licence avec Prestige Biopharma, pour la commercialisation de Tuznue® (trastuzumab), un biosimilaire d’Herceptin®, sur la plupart des marchés européens....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
TEVA
LISTED
TLV
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
News Preview
TEL AVIV, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue® (trastuzumab), a biosimilar to Herceptin®, across a majority of European markets....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.10.2025
TEVA
LISTED
TLV
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
News Preview
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has approved UZEDY® (risperidone) as a once-monthly extended-relea...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
25.09.2025
TEVA
LISTED
TLV
Teva Releases Q3 2025 Aide Memoire
News Preview
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its website....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2025
TEVA
LISTED
TLV
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
News Preview
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day,...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.09.2025
TEVA
LISTED
TLV
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
News Preview
PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of data from a real-world survey of patients taking AUSTEDO XR® (deutetrabenazine) extended-release tablets. Patients taking AUSTEDO XR rep...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.09.2025
TEVA
LISTED
TLV
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
News Preview
PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of 10 posters from its innovative schizophrenia medicines portfolio, including long-term safety data from the completed SOLARIS Phase 3 tri...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
TEVA
LISTED
TLV
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
News Preview
TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California....
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
TEVA
LISTED
TLV
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
News Preview
TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in September as follows:...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2025
TEVA
LISTED
TLV
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
News Preview
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2025
TEVA
LISTED
TLV
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
News Preview
Q2 2025 Highlights:...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2025
TEVA
LISTED
TLV
Teva Releases Q2 2025 Aide Memoire
News Preview
TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its website....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.06.2025
TEVA
LISTED
TLV
Abschließende Daten aus der realen PEARL-Studie von Teva untermauern die langfristige Wirksamkeit von AJOVY® (fremanezumab) für die Prävention chronischer und episodischer Migräne
News Preview
TEL AVIV, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) gab heute bekannt, dass die abschließende Analyse der paneuropäischen Phase-IV-PEARL-Studie für die Prävention von Migräne zeige, dass AJOVY (fremanezumab), ein monoklonaler CGRP (Anti-Calcitonin Gene-Related Peptide)-Antikörper, über ein...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.06.2025
TEVA
LISTED
TLV
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
News Preview
TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevention study showed that AJOVY (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness ov...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2025
TEVA
LISTED
TLV
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
News Preview
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously announced tender offers (the “Offers”) to purchase for cash the outstanding notes issued by finance subsidiaries of Teva and guaranteed by Teva of the ser...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2025
TEVA
LISTED
TLV
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
News Preview
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.05.2025
TEVA
LISTED
TLV
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
News Preview
PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a study of treatment patterns among patients with tardive dyskinesia (TD) residing in long-term care (LTC) facilities, highlighting a critical gap...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.05.2025
TEVA
LISTED
TLV
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with T
News Preview
PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of real-world clinical outcomes, treatment patterns and healthcare resource utilization (HCRU) data evaluating UZEDY® (risperidone), an extend...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.05.2025
TEVA
LISTED
TLV
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
News Preview
TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is hosting today a 2025 Innovation & Strategy Day, to launch the acceleration phase of its “Pivot to Growth” strategy and to discuss portfolio priorities as it evolves into a global biopharmaceutical leader. The e...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.05.2025
TEVA
LISTED
TLV
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
News Preview
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2025
TEVA
LISTED
TLV
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
News Preview
TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it is increasing the maximum tender amount of its tender offer previously announced on May 19, 2025 from $2.0 billion (equivalent) aggregate cash purchase price (exclusive of accrued and unpaid interest) to ap...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.05.2025
TEVA
LISTED
TLV
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
News Preview
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the “Notes”). The principal amount of the offering was increased from the previously announced off...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.05.2025
TEVA
LISTED
TLV
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
News Preview
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it has commenced tender offers (the “Offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,000,000,000 (equivalent) (the “Total Maximum Am...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.05.2025
TEVA
LISTED
TLV
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
News Preview
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $2,000,000,000 (equivalent) of senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denomina...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2025
TEVA
LISTED
TLV
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
News Preview
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2025
TEVA
LISTED
TLV
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
News Preview
For an accessible version of this Press Release, please visit www.tevapharm.com...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.03.2025
TEVA
LISTED
TLV
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
News Preview
PARSIPPANY, N.J. and TEL AVIV, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Ola...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.03.2025
TEVA
LISTED
TLV
Teva Releases Q1 2025 Aide Memoire
News Preview
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its website....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.02.2025
TEVA
LISTED
TLV
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
News Preview
The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.02.2025
TEVA
LISTED
TLV
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
News Preview
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.02.2025
TEVA
LISTED
TLV
Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern
News Preview
AMSTERDAM, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Laut einer neuen Studie von Teva Pharmaceuticals Europe werden 46 % der Generika auf der EU-Liste der kritischen Arzneimittel von nur einem Anbieter bereitgestellt. Wenn man Anbieter mit einem Marktanteil von über 60 % betrachtet, verdoppelt sich diese Zahl auf 83 %. Die Studie Generic Health Check Eur...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.02.2025
TEVA
LISTED
TLV
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
News Preview
PARSIPPANY, N.J. and REYKJAVÍK, Iceland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI™ (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara® (ustekinumab), for the tre...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
